Search by Drug Name or NDC
NDC 71287-0119-02 YESCARTA 2000000 1/68mL Details
YESCARTA 2000000 1/68mL
YESCARTA is a INTRAVENOUS SUSPENSION in the CELLULAR THERAPY category. It is labeled and distributed by Kite Pharma, Inc.. The primary component is AXICABTAGENE CILOLEUCEL.
MedlinePlus Drug Summary
Axicabtagene ciloleucel injection is used to treat a certain type of non-Hodgkin's lymphoma (cancer that begins in white blood cells that normally fight infection) that has returned or is unresponsive to other treatment(s) in people who have already been treated with at least two other chemotherapy medications. Axicabtagene ciloleucel injection is in a class of medications called autologous cellular immunotherapy, a type of medication prepared using cells from the patient's own blood. It works by causing the body's immune system (a group of cells, tissues, and organs that protects the body from attack by bacteria, viruses, cancer cells, and other substances that cause disease) to fight the cancer cells.
Related Packages: 71287-0119-02Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Axicabtagene Ciloleucel Injection
Product Information
| NDC | 71287-0119 |
|---|---|
| Product ID | 71287-119_88838c18-3786-48ce-975c-06e1cd63ece4 |
| Associated GPIs | 21651010101820 |
| GCN Sequence Number | 077829 |
| GCN Sequence Number Description | axicabtagene ciloleucel PLAST. BAG INTRAVEN |
| HIC3 | V35 |
| HIC3 Description | ANTINEOPLASTIC - CAR-T CELL IMMUNOTHERAPY |
| GCN | 43978 |
| HICL Sequence Number | 044577 |
| HICL Sequence Number Description | AXICABTAGENE CILOLEUCEL |
| Brand/Generic | Brand |
| Proprietary Name | YESCARTA |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | axicabtagene ciloleucel |
| Product Type | CELLULAR THERAPY |
| Dosage Form | SUSPENSION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 2000000 |
| Active Ingredient Units | 1/68mL |
| Substance Name | AXICABTAGENE CILOLEUCEL |
| Labeler Name | Kite Pharma, Inc. |
| Pharmaceutical Class | CD19 Receptor Interactions [MoA], CD19-directed Chimeric Antigen Receptor [EPC], CD19-specific Chimeric Antigen Receptor [CS], Genetically-modified Autologous T Cells [EPC], Increased T Lymphocyte Activation [PE], T Lymphocytes, Cultured, Autologous, Gene |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA125643 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 71287-0119-02 (71287011902)
| NDC Package Code | 71287-119-02 |
|---|---|
| Billing NDC | 71287011902 |
| Package | 1 BAG in 1 PACKAGE (71287-119-02) / 68 mL in 1 BAG (71287-119-01) |
| Marketing Start Date | 2017-10-18 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |